Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Manufacturing Woes Result In “Complete Response” For Lilly’s Empagliflozin

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Some analysts expect it could take six months to resolve problems at partner Boehringer Ingelheim’s German manufacturing site, where the SGLT-2 inhibitor is made. Lilly says the European filing is not affected.

Advertisement

Related Content

BI/Lilly Bring Third Entrant To SGLT2 Market With Jardiance Approval
Empagliflozin Approval May Come This Year After Boehringer Resolves GMP Problems
Empagliflozin Approval May Come This Year After Boehringer Resolves GMP Problems
AstraZeneca’s Farxiga Label Includes, But Downplays, Bladder Cancer Risk
J&J Gains FDA OK For First-In-Class Type 2 Diabetes Drug Invokana
Boehringer/Lilly To Price Tradjenta On Par With Rival DPP-4 Inhibitors

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS005685

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel